Navigation Links
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Date:1/31/2008

/or INTRON(R) A be discontinued, and the patient be carefully followed with psychiatric intervention, as appropriate. Cases of encephalopathy have been observed in some patients, usually elderly, treated with higher doses of PEGINTRON(TM) and/or INTRON(R) A.

Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with interferon alpha therapies, including PEGINTRON(TM) and INTRON(R) A.

Full prescribing information can be found at http://www.schering-plough.com.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE:

The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to any future market potential for peginterferon alfa-2b. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement.

Many fa
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... CA (PRWEB) June 02, 2015 German-based ... official United States distributor for the Moenninghoff product ... stated, “I am pleased to announce that the R.M. ... market. For our firm, founded in 1916, this is ... R.M. Hoffman is the kind of professional distributor we ...
(Date:6/1/2015)... 1, 2015 Research ... the addition of the "Oxidative Stress ... Test Type (Indirect, Enzyme-based, Reactive Oxygen Species ... Users - Global Forecast to 2020" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , The global ...
(Date:6/1/2015)... 2015 About Bio-alcohols Bio-alcohols ... or cellulose. Bio-alcohols are primarily used in the transportation ... replacement for gasoline in cars. Technavio,s analysts forecast the ... 9 percent over the period 2014-2019. ... be segmented into five: transportation, infrastructure, medical, and others. ...
(Date:6/1/2015)...  The Val Skinner Foundation is partnering with Discovery ... high school students focused on cancer genetics. Skinner made ... Event (LPGA Pros in the Fight to Eradicate breast ... West Caldwell, N.J. Skinner ... than $500,000 on Monday, bringing the foundation,s 16-year total ...
Breaking Biology Technology:R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Global Bio-alcohols Market 2015-2019 2Val Skinner Foundation Announces Partnership With Discovery Education 2
... May 25, 2011 /PRNewswire/ -- Vermillion, ... today announced that the United States Patent and Trademark Office ... entitled "Saposin D and Fam3C are Biomarkers for Alzheimer,s Disease." ... as well as combinations that include these biomarkers. ...
... 2011 VIVUS, Inc. (NASDAQ: ... 3, placebo-controlled clinical trial of the investigational drug avanafil ... following a radical prostatectomy. The study (REVIVE-RP, TA-303) met ... erectile function as measured by the Sexual Encounter Profile ...
... 24, 2011 Spherix Incorporated (NASDAQ: ... in diabetes, metabolic syndrome and atherosclerosis, and providers ... supplement, biotechnology and pharmaceutical companies – today announced ... rule 5550(a)(2), which concerns minimum bid price listing ...
Cached Biology Technology:Vermillion Announces Notice of Allowance for Alzheimer Patent 2Vermillion Announces Notice of Allowance for Alzheimer Patent 3VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 2VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 3VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 4VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 5Spherix Regains Compliance With NASDAQ Listing Rule 2
(Date:5/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... LLC, a company engaged in biometric identification is an ... portion of the recently awarded TIES (Technical Information Engineering ... Army. 3D-ID LLC has a suite of ... and security agencies. Gino Pereira , ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... levels of folate in their red blood cells were more ... a chemical off switch for genes, researchers report in the ... co-author Jean-Pierre Issa, M.D., professor in MD Anderson,s Department of ... of aging, such as heart disease. Methyl groups attach to ...
... 2010)A class of drugs thought to kill cancer cells may ... normal immune cells, resulting in reduced cancer growth and spreada ... evaluated in the future. Researchers at the University of ... fifth most common cancer in the United States. Bladder cancer ...
... release of an online tool that will help scientists ... a cell,s transcription machinery where to start reading in ... Promoter Database (MPromDb) integrates the genome sequencing data generated ... mouse genomics. MPromDb pinpoints known promoters and predicts where ...
Cached Biology News:High red blood cell folate levels linked to silenced tumor-suppressors 2High red blood cell folate levels linked to silenced tumor-suppressors 3Some cancer drugs may block cellular 'cross talk' but not kill cancer cells 2New annotated database sifts through mountains of sequencing data to find gene promoters 2New annotated database sifts through mountains of sequencing data to find gene promoters 3
... Factor XIII in both reduced and non-reduced ... XIII B-chain or human Factor XII. Factor XIII ... composed of two subunits. Factor XIII-A is the ... 160kDa. Factor XIII is present in plasma as ...
... Anti-Lipid Phosphate Phosphatase 2 ... buffered aqueous solution ... saline containing 0.08% sodium ... from the human LPP2 ...
Anti-CaM kinase II recognizes the enzymes a subunit (6) and reacts with tissue from all mammalian species tested, as well as with chicken and frog tissues....
... Anti-MAPKAPK-2, Phospho-Specific(Thr 222 ) ... NaCl, 10 mM sodium HEPES, ... pH 7.5. Recognizes the ~47 ... 2 (MAPKAPK-2) protein phosphorylated at ...
Biology Products: